Pain clinic CEO made patients ‘human pin cushions.’ He got 18 months


By Brett Kelman, KFF Health News

NASHVILLE, Tenn. — Federal prosecutors sought a maximum prison sentence of nearly 20 years for the CEO of Pain MD, a company found to have given hundreds of thousands of questionable injections to patients, many reliant on opioids. It would have been among the longest sentences for a health care executive convicted of fraud in recent years.

Instead, he got 18 months.

Michael Kestner, 73, who was convicted of 13 fraud felonies last year, faced at least a decade behind bars based on federal sentencing guidelines. He was granted the substantially lightened sentence due to his age and health Wednesday during a federal court hearing in Nashville.

U.S. District Judge Aleta Trauger described Kestner as a “ruthless businessman” who funded a “lavish lifestyle” by turning medical professionals into “puppets” who pressured patients into injections that did not help their pain and sometimes made it worse.

“In the court’s eyes, he knew it was wrong, and he didn’t really care if it was doing anyone any good,” Trauger said.

But Trauger also said she was swayed by defense arguments that Kestner would struggle in federal prison due to his age and medical conditions, including the blood disorder hemochromatosis. Trauger said she had concerns about prison health care after considering about 200 requests for compassionate release in other court cases.

“The medical care at these facilities,” defense attorney Peter Strianse said, “has always been dodgy and suspect.”

Kestner did not speak at the court hearing, other than to detail his medical conditions. He did not respond to questions as he left the courthouse.

Pain MD CEO Michael Kestner leaves a federal courthouse in Nashville, Tennessee, followed by one of his lawyers, after being sentenced to 18 months in federal prison on May 14, 2025. ((Brett Kelman/KFF Health News)/KFF Health News/TNS)
Pain MD CEO Michael Kestner leaves a federal courthouse in Nashville, Tennessee, followed by one of his lawyers, after being sentenced to 18 months in federal prison on May 14, 2025. ((Brett Kelman/KFF Health News)/KFF Health News/TNS)

Pain MD ran as many as 20 clinics in Tennessee, Virginia, and North Carolina throughout much of the 2010s. While many doctors were scaling back their use of prescription painkillers due to the opioid crisis, Pain MD paired opioids with monthly injections into patients’ backs, claiming the shots could ease pain and potentially lessen reliance on pills, according to federal court documents.

During Kestner’s October trial, the Department of Justice proved that the injections were part of a decade-long scheme that defrauded Medicare and other insurance programs of millions of dollars by capitalizing on patients’ dependence on opioids.

The DOJ successfully argued at trial that Pain MD’s “unnecessary and expensive injections” were largely ineffective because they targeted the wrong body part, contained short-lived numbing medications but no steroids, and appeared to be based on test shots given to cadavers — people who felt neither pain nor relief because they were dead. During closing arguments, the DOJ argued Pain MD had turned some patients into “human pin cushions.”

“They were leaned over a table and repeatedly injected in their spine,” federal prosecutor Katherine Payerle said during the May 14 sentencing hearing. “Over and over, month after month, at the direction of Mr. Kestner.”



Source link

Leave a Reply

Subscribe to Our Newsletter

Get our latest articles delivered straight to your inbox. No spam, we promise.

Recent Reviews


This article was written by

I am an individual investor with over 10 years of trading. I have been developing as a stock analyst for the last five years. I am inclined to search for Value companies, mainly linked to the production of commodities. I mainly focus on companies that show sustained free cash flows over time, low levels of leverage, sustainable debt over time, that are going through some stage of distress but with high recovery potential. I prefer to analyze companies and sectors that are not widely taken into account by the market like oil&gas, metals, minery and and companies operating in jurisdictions outside the United States, as an opportunity to find value. In that sense, I focus on companies that are developed in emerging markets, that show high margins and present good investment opportunities in the medium and long term. I am interested in companies with a solid pro-shareholder attitude, that maintain solid and sustained buyback programs over time or dividend distribution.I finished my financial master degree with a specialization in company valuation. I vave an economic degree too. One of my main motivations is to share information about companies with the seeking alpha community of investors and add value to the individual decisions of readers. I am not a financial advisor. I maintain a friendship with another author of the page, Eliseo Bottini Antunes. This is not based on any business or commercial connection between the two. We each cover different sectors and companies with different points of view and opinions. All articles are my opinion – they are not suggestions to buy or sell any securities

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.



Source link